Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


New Active Substance First Launches Rebound In 2017

2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.

Approvals Commercial Research & Development

Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche

Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.

Sales & Earnings Business Strategies Commercial

Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges

New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.

Clinical Trials ImmunoOncology Research and Development Strategies
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Set Alert for Commercial

Biogen Re-Ups With Ionis In Search Of A Neuroscience 'Innovation Engine'

New 10-year collaboration, the sixth between the two firms, will attempt to bring seven antisense candidates for neurological indications to the clinic in the next two years. Biogen pays $1bn up front, split between cash and Ionis equity.
Deals Research & Development Neurology

Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’

Merck KGaA’s sale of its global consumer health business to Procter & Gamble (P&G) is expected to be a somewhat complex affair in emerging markets like India, where it has a listed entity and a seemingly cohesive consumer health and pharma footprint, though Merck's management emphasized that no “dis-syneries” are anticipated.

M & A India Consumer

Sweet Enough? Takeda Raises, Adds Cash To Shire Offer

Takeda has further bumped up its offer for acquisition target Shire, raising the per share price and cash component, in what the Japanese firm says is a “compelling” proposal worth well over $60bn. Will it be fourth time lucky?

Japan Commercial

STORM CEO Outlines Business Model And Pipeline Goals

Keith Blundy, CEO of STORM Therapeutics, discusses the companys founding and upcoming milestones.  

Business Strategies Commercial

Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid

Takeda's most recent offer for Shire had an estimated total value of $61bn, but likely included too much equity and too little cash. The companies continue negotiating as an April 25 deadline looms, while Allergan stated it won't bid for Shire.
M & A Business Strategies

Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows

A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing. 

Pricing Strategies Pricing Debate

US Generic Drug Spending Declines In A New Development – IQVIA Report

Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.

Generic Drugs Biosimilars

Novartis Allays Concerns Over Cosentyx Sales Miss

The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.

Sales & Earnings Dermatology

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Approval Of GW Pharma's Cannabidiol Epidiolex 'No Longer A Pipe Dream'

Set to be the first FDA-approved cannabidiol-based drug, Epidiolex would treat seizures associated with the rare childhood epilepsy indications Lennox-Gastaut syndrome and Dravet syndrome.

Advisory Committees Approvals Business Strategies

China Vs Cancer: An Infographic Snapshot

Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs  from May.

Cancer China

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.

Business Strategies Companies

India Leads Global 65% Surge In Antibiotics Use

Human antibiotic consumption globally jumped dramatically between 2000 and 2015, with India posting the biggest rise, reports a new US study, which calls for a radical policy rethink to prevent antimicrobial drug resistance soaring.

India Policy & Regulation

Research & Development Explore this Topic

Set Alert for Research & Development

Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals Research & Development

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.

Research & Development Liver & Hepatic

Publisher's Spotlight: The 2018 Scrip Awards Is Now Open For Entries

Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for entries.

Companies Research & Development

Experts Challenge GSK Triple Inhaled COPD Therapy Claims

While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.

Clinical Trials Research & Development
UsernamePublicRestriction

Register

Advertisement